Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA E545K |
Therapy | Alpelisib |
Indication/Tumor Type | cervical cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA E545K | cervical cancer | predicted - sensitive | Alpelisib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Piqray (alpelisib) increased apoptosis and decreased colony formation in a cervical cancer cell line harboring PIK3CA E545K in culture and decreased tumor cell proliferation and increased CD8-positive T-cell differentiation and proliferation in a cell line xenograft model (PMID: 37469254). | 37469254 |
PIK3CA E545K | cervical cancer | predicted - sensitive | Alpelisib | Case Reports/Case Series | Actionable | In a Phase I trial, treatment with Piqray (alpelisib) resulted in an objective response rate of 33% (2/6; all partial responses), disease control rate of 100% (6/6), with stable disease in 5 patients, in cervical cancer patients harboring PIK3CA mutations, including PIK3CA E545K (PMID: 35311394). | 35311394 |
PubMed Id | Reference Title | Details |
---|---|---|
(35311394) | BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer. | Full reference... |
(37469254) | Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer. | Full reference... |